These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 28705005)
1. Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities. Robin TP; Goodman KA Chin Clin Oncol; 2017 Jun; 6(3):28. PubMed ID: 28705005 [TBL] [Abstract][Full Text] [Related]
2. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. Chapman BC; Gleisner A; Rigg D; Meguid C; Goodman K; Brauer B; Gajdos C; Schulick RD; Edil BH; McCarter MD J Surg Oncol; 2018 Apr; 117(5):1073-1083. PubMed ID: 29448308 [TBL] [Abstract][Full Text] [Related]
3. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288 [TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581 [TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768 [TBL] [Abstract][Full Text] [Related]
10. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876 [TBL] [Abstract][Full Text] [Related]
11. The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings. Franke AJ; Rosati LM; Pawlik TM; Kumar R; Herman JM Semin Oncol; 2015 Feb; 42(1):144-62. PubMed ID: 25726059 [TBL] [Abstract][Full Text] [Related]
12. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157 [TBL] [Abstract][Full Text] [Related]
13. Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Hall WA; Goodman KA Radiat Oncol; 2019 Jun; 14(1):114. PubMed ID: 31242912 [TBL] [Abstract][Full Text] [Related]
14. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). Shaib WL; Hawk N; Cassidy RJ; Chen Z; Zhang C; Brutcher E; Kooby D; Maithel SK; Sarmiento JM; Landry J; El-Rayes BF Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):296-303. PubMed ID: 27475674 [TBL] [Abstract][Full Text] [Related]
15. Locally advanced pancreatic cancer: An emerging entity. O Kane GM; Knox JJ Curr Probl Cancer; 2018; 42(1):12-25. PubMed ID: 29153290 [TBL] [Abstract][Full Text] [Related]
16. [Stereotactic body radiotherapy for locally advanced pancreatic cancer: A systemic review]. Tonneau M; Lacornerie T; Mirabel X; Pasquier D Cancer Radiother; 2021 May; 25(3):283-295. PubMed ID: 33423968 [TBL] [Abstract][Full Text] [Related]
17. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Badiyan SN; Molitoris JK; Chuong MD; Regine WF; Kaiser A Surg Oncol Clin N Am; 2017 Jul; 26(3):431-453. PubMed ID: 28576181 [TBL] [Abstract][Full Text] [Related]
18. The Current Role of Radiation in Pancreatic Cancer and Future Directions. Hill CS; Herman JM Clin Colorectal Cancer; 2023 Mar; 22(1):12-23. PubMed ID: 36804206 [TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design. Hoffe SE; Aguilera TA; Parikh PJ; Ghaly MM; Herman JM; Caster JM; Kim DW; Costello J; Malafa MP; Moser EC; Kennedy EP; Terry K; Kurman M Future Oncol; 2024 Mar; 20(8):437-446. PubMed ID: 38264869 [TBL] [Abstract][Full Text] [Related]
20. Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy. De Bari B; Porta L; Mazzola R; Alongi F; Wagner AD; Schäfer M; Bourhis J; Ozsahin M Crit Rev Oncol Hematol; 2016 Jul; 103():49-61. PubMed ID: 27233119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]